中国新诊断高血压患者中原发性醛固酮增多症患病率研究
该前瞻性研究在中国社区健康中心筛查1020例新诊断高血压患者,发现原发性醛固酮增多症患病率至少4.0%。手术患者生化完全成功率100%、临床完全成功率85.7%;药物治疗患者血压达标率79%,其中91%仅需一种降压药(盐皮质激素受体拮抗剂)。
要点
- 新诊断高血压患者中原发性醛固酮增多症患病率至少4.0%
- 原发性醛固酮增多症患者微量白蛋白尿更常见,但心血管事件发生率无差异
- 筛查后手术或药物治疗均可获得良好临床结局
核心结论
- 中国新诊断高血压患者中原发性醛固酮增多症患病率至少为4.0%。
- 对新诊断高血压患者进行原发性醛固酮增多症筛查可带来良好的临床结局。
研究设计与样本
- 前瞻性研究,在大型社区健康中心连续纳入新诊断高血压患者。
- 共筛查1020例新诊断高血压患者,历时16个月。
- 醛固酮肾素比值>20 ng/mIU且血浆醛固酮浓度>10 ng/dl者接受卡托普利激发试验和/或盐水输注试验确诊。
- 采用肾上腺计算机断层扫描和肾上腺静脉采血进行分型。
- 手术或药物治疗的原发性醛固酮增多症患者随访1年评估结局。
主要发现
- 1020例中40例诊断为原发性醛固酮增多症,948例为非原发性醛固酮增多症,32例为可能原发性醛固酮增多症,患病率超过4.0%。
- 与非原发性醛固酮增多症患者相比,原发性醛固酮增多症患者微量白蛋白尿更常见(p=0.031)。
- 原发性醛固酮增多症与非原发性醛固酮增多症患者心血管事件发生率无差异(p=0.927)。
- 手术治疗患者(n=7)生化完全成功率100%,临床完全成功率85.7%。
- 药物治疗患者(n=29)血压最佳控制比例为79%,其中91%(23例中21例)仅需一种降压药即盐皮质激素受体拮抗剂。
关键数值与推荐
- 筛查标准:醛固酮肾素比值>20 ng/mIU且血浆醛固酮浓度>10 ng/dl。
- 确诊试验:卡托普利激发试验和/或盐水输注试验。
- 分型方法:肾上腺计算机断层扫描和肾上腺静脉采血。
临床怎么用
- 对新诊断高血压患者应考虑筛查原发性醛固酮增多症。
- 确诊后根据分型选择手术或盐皮质激素受体拮抗剂治疗,均可获得良好结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: A total of 44.7% adults in China have hypertension, but the prevalence of primary aldosteronism (PA) in Chinese hypertensive patients is unknown. OBJECTIVES: This study prospectively investigated the prevalence, characteristics, and outcomes of PA in newly diagnosed hypertensive patients. METHODS: In a large community health center, consecutive hypertensive patients with an aldosterone-renin ratio >20 ng/mIU and plasma aldosterone concentration >10 ng/dl underwent captopril challenge test and/or saline infusion test for confirmation of PA. Adrenal computed tomography scan and adrenal vein sampling were used for subtyping. PA patients treated with surgery or medication were followed up for 1 year, and outcomes after treatment were evaluated. RESULTS: In total, 1,020 newly diagnosed hypertensive patients were screened over 16 months, of whom 40 were diagnosed with PA, 948 with non-PA, 32 with probable PA, resulting in a prevalence of more than 4.0%. Compared with non-PA, PA patients more frequently displayed microalbuminuria (p = 0.031), but the incidence of cardiovascular events was not different (p = 0.927). For surgically treated patients (n = 7), a complete biochemical success rate was 100% and a complete clinical success rate was 85.7%. For medically treated patients (n = 29), the proportion with optimal blood pressure control was 79%, and among them, 91% (21 of 23) only needed 1 antihypertensive drug: the mineralocorticoid receptor antagonist. CONCLUSIONS: The prevalence of PA in patients with newly diagnosed hypertension in China was at least 4%. PA screening in newly diagnosed hypertensive patients leads to good clinical outcomes. (Primary Aldosteronism In Hypertensive Patients in China [PA-China]; NCT03155139).
引用
- Xu Z, Yang J, Hu J, et al. Primary Aldosteronism in Patients in China With Recently Detected Hypertension. J Am Coll Cardiol. 2020. PMID: 32327102. doi:10.1016/j.jacc.2020.02.052
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。